题名

Ex vivo and in vitro inhibitory potential of Kava extract on monoamine oxidase B activity in mice

DOI

10.1016/j.jtcme.2021.07.002

作者

Bárbara Nunes Krum；Catiuscia Molz de Freitas；Alcindo Busanello；Larissa Finger Schaffer；Roselei Fachinetto

关键词

Piper methysticum ； Open field ； Plus maze ； Kynuramine ； Anxiety

期刊名称

Journal of Traditional and Complementary Medicine

卷期/出版年月

12卷2期（2022 / 03 / 01）

页次

115 - 122

内容语文

英文
中文摘要

Background and aim: This study investigated the effect of Kava extract (Piper methysticum), a medicinal plant that has been worldly used by its anxiolytic effects, on monoamine oxidase (MAO) activity of mice brain after 21 days of treatment as well as anxiolytic and locomotor behavior. Furthermore, the in vitro inhibitory profile of Kava extract on MAO-B activity of mouse brain was evaluated. Experimental procedure: Mice were treated with Kava extract (10, 40, 100 and 400 mg/kg) for 21 days by gavage. After behavioral analysis (plus maze test and open field), MAO activity in different mouse brain structures (cortex, hippocampus, region containing the substantia nigra and striatum) were performed. MAO-B inhibitory profile was characterized in vitro. Results: The treatment with Kava extract (40 mg/kg) increased the percentage of entries of mice into the open arms. Ex vivo analysis showed an inhibition on MAO-B activity caused by Kava extract in cortex (10 mg/kg) and in the region containing the substantia nigra (10 and 100 mg/kg). In vitro, Kava extract also reversibly inhibited MAO-B activity with IC_(50) = 14.62 μg/mL and, increased Km values at the concentrations of 10 and 30 μg/mL and decreased Vmax value at 100 μg/mL. Conclusion: Kava extract showed different effects on MAO-B isoform depending on the brain structure evaluated. Therefore, the use of Kava extract could be promissory in pathologies where MAO-B is the pharmacological target.
主题分类 醫藥衛生 > 中醫藥學
参考文献
  1. FDA Listing of Established Pharmacologic Class Text Phrases January 2021. Available in: https://www.fda.gov/media/144963/download. Accessed July 1, 2021.
  2. Abu, N,Ho, W,Yeap, S(2013).The flavokawains: uprising medicinal chalcones.Canc Cell Int,13(1),102.
  3. Anchan, D,Clark, S,Pollard, K,Vasudevan, N(2014).GPR30 activation decreases anxiety in the open field test but not in the elevated plus maze test in female mice.Brain Behav,4(1),51-59.
  4. Bach, AW,Lan, NC,Johnson, DL(1988).cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties.Proc Natl Acad Sci U S A,85(13),4934-4938.
  5. Behl, M,Nyska, A,Chhabra, RS(2011).Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to Kava Kava.Food Chem Toxicol,49(11),2820-2829.
  6. Blazevic, S,Merkler, M,Persic, D,Hranilovic, D(2017).Chronic postnatal monoamine oxidase inhibition affects affiliative behavior in rat pupso.Pharmacol Biochem Behav,153,60-68.
  7. Blumenthal, M(2005).Kava: from Ethnology to Ethnopharmacology By Yadhu N. Singh (South Dakota State University). CRC Press, Boca Raton. 2004. vii +167 pp. 7 ×10 1/4 in. $99.95. ISBN 3-415-32327-4.J Nat Prod,68(1),152-153.
  8. Bortolato, M,Godar, SC,Davarian, S,Chen, K,Shih, JC(2009).Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase b-deficient mice.Neuropsychopharmacology,34(13),2746-2757.
  9. Busanello, A,Barbosa, NBV,Peroza, LR(2011).Resveratrol protects against a model of vacuous chewing movements induced by reserpine in mice.Behav Pharmacol,22(1),71-75.
  10. Busanello, A,Leal, CQ,Peroza, LR(2017).Resveratrol protects against vacuous chewing movements induced by chronic treatment with Fluphenazine.Neurochem Res,42(11),3033-3040.
  11. Cairney, S,Maruff, P,Clough, AR(2002).The neurobehavioural effects of kava.Aust N Z J Psychiatr,36(5),657-662.
  12. Cawte, J(1986).Parameters of kava used as a challenge to alcohol.Aust N Z J Psychiatr,20(1),70-76.
  13. Chua, HC,Christensen, ETH,Hoestgaard-Jensen, K(2016).Kavain, the major constituent of the anxiolytic kava extract, potentiates gabaa receptors: Functional characteristics and molecular mechanism.PLoS One,11(6),e0157700.
  14. Cohen, G,Farooqui, R,Kesler, N(2002).Parkinson disease: a new link between mono-amine oxidase and mitochondrial electron flow.Proc Natl Acad Sci Unit States Am.,94(10),4890-4894.
  15. de Oliveira, DR,Schaffer, LF,Busanello, A(2015).Silymarin has antioxidant potential and changes the activity of Na+/K+-ATPase and monoamine oxidase in vitro.Ind Crop Prod,70,347-355.
  16. Dezsi, L,Vecsei, L(2017).Monoamine Oxidase B Inhibitors in Parkinson's Disease.CNS Neurol Disord - Drug Targets,16(4),425-439.
  17. Di Giovanni, G,Strac, DS,Sole, M(2016).Monoaminergic and histaminergic strategies and treatments in brain diseases.Front Neurosci,10,541.
  18. Dinh, LD,Simmen, U,Bueter, KB,Bueter, B,Lundstrom, K,Schaffner, W(2001).Interaction of various Piper methysticum cultivars with CNS receptors in vitro.Planta Med.,67(4),306-311.
  19. Edmondson, DE,Binda, C,Wang, J,Upadhyay, AK,Mattevi, A(2009).Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases.Biochemistry,48(20),4220-4230.
  20. Fachinetto, R,Villarinho, JG,Wagner, C(2007).Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter.Prog Neuro-Psychopharmacol Biol Psychiatry,31(7),1478-1486.
  21. Figueira, FH,Leal, CQ,de Moraes Reis, E(2015).Effects of diphenyl diselenide on behavioral and biochemical changes induced by amphetamine in mice.J Neural Transm,122(2),201-209.
  22. Finberg, JPM,Rabey, JM(2016).Inhibitors of MAO-A and MAO-B in psychiatry and neurology.Front Pharmacol,7,340.
  23. Fu, PP,Xia, Q,Guo, L,Yu, H,Chan, PC(2008).Toxicity of kava kava.J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev,26(1),89-112.
  24. Guglielmi, P,Mathew, B,Secci, D,Carradori, S(2020).Chalcones: Unearthing their therapeutic possibility as monoamine oxidase B inhibitors.Eur J Med Chem,205,112650.
  25. Harfenist, M,Heuser, DJ,Joyner, CT,Batchelor, JF,White, HL(1996).Selective inhibitors of monoamine oxidase. 3. Structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups.J Med Chem,39(9),1857-1863.
  26. Jamieson, DD,Duffield, PH(1990).The antinociceptive actions of kava components IN mice.Clin Exp Pharmacol Physiol,17(7),495-507.
  27. Johns, T(1993).Kava: the Pacific drug. Psychoactive plants of the World. Vincent Lebot , Mark Merlin , Lamont Lindstrom.Q Rev Biol,256
  28. Kim, D,Baik, SH,Kang, S(2016).Close correlation of monoamine oxidase activity with progress of Alzheimer's disease in mice, observed by in vivo two-photon imaging.ACS Cent Sci.,2(12),967-975.
  29. Krum, BN,Molz de Freitas, C,Chiapinotto Ceretta, AP(2020).Kava decreases the stereotyped behavior induced by amphetamine in mice.J Ethnopharmacol,265,113293.
  30. Lebot, V,Do, TKT,Legendre, L(2014).Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC).Food Chem,151,554-560.
  31. Li, L,Zhang, CW,Chen, GYJ(2014).A sensitive two-photon probe to selectively detect monoamine oxidase B activity in Parkinson's disease models.Nat Commun,5,3276.
  32. Lieu, CA,Chinta, SJ,Rane, A,Andersen, JK(2013).Age-Related Behavioral Phenotype of an Astrocytic Monoamine Oxidase-B Transgenic Mouse Model of Parkinson's Disease.PLoS One,8(1),e54200.
  33. Liu, Y,Lund, JA,Murch, SJ,Brown, PN(2018).Single-lab validation for determination of kavalactones and flavokavains in piper methysticum (kava).Planta Med,84(16),1213-1218.
  34. Lowry(1951).Lowry. Protein assay.J Biol Chem,193(1),265-275.
  35. Mathew, B.(2020).Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer's Treatment.Comb Chem High Throughput Screen,23(9),842-846.
  36. Mathew, B,Suresh, J,Mathew, G,Parasuraman, R,Abdulla, N(2014).Plant Secondary Metabolites- Potent Inhibitors of Monoamine Oxidase Isoforms.Cent Nerv Syst Agents Med Chem,14(1),28-33.
  37. Morinan, A,Garratt, HM(1985).An improved fluorimetric assay for brain monoamine oxidase.J Pharmacol Methods,13(3),213-223.
  38. Prinsloo, D,Van Dyk, S,Petzer, A,Petzer, JP(2019).Monoamine Oxidase Inhibition by Kavalactones from Kava (Piper Methysticum).Planta Med,85(14-15),1136-1142.
  39. Reagan-Shaw, S,Nihal, M,Ahmad, N(2007).Dose translation from animal to human studies revisited.Faseb J.,22(3),659-661.
  40. Reinheimer, JB,Bressan, GN,de Freitas, CM(2020).Effects of CATECHIN on reserpine-induced vacuous chewing movements: behavioral and biochemical analysis.Naunyn-Schmiedeberg’s Arch Pharmacol,393(12),2439-2452.
  41. Roze, E,Bonnet, C,Betuing, S,Caboche, J(2010).Huntington's disease.Adv Exp Med Biol,685,45-63.
  42. Sällström, Baum, S,Hill, R,Rommelspacher, H(1998).Effect of kava extract and indi- € vidual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats.Prog Neuro-Psychopharmacol Biol Psychiatry,22(7),1105-1120.
  43. Sarris, J,Kavanagh, DJ,Adams, J,Bone, K,Byrne, G(2009).Kava Anxiety Depression Spectrum Study (KADSS): A mixed methods RCT using an aqueous extract of Piper methysticum.Compl Ther Med,17(3),176-178.
  44. Sarris, J,Laporte, E,Schweitzer, I(2011).Kava: a comprehensive review of efficacy, safety, and psychopharmacology.Aust N Z J Psychiatr,45(1),27-35.
  45. Sarris, J,Scholey, A,Schweitzer, I(2012).The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study.Hum Psychopharmacol,27(3),262-269.
  46. Saura, J,Andres, N,Andrade, C,Ojuel, J,Eriksson, K,Mahy, N(1997).Biphasic and region-specific MAO-B response to aging in normal human brain.Neurobiol Aging,18(5),497-507.
  47. Schelosky, L,Raffauf, C,Jendroska, K,Poewe, W(1995).Kava and dopamine antagonism.J Neurol Neurosurg Psychiatry,58(5),639-640.
  48. Singh, YN(1992).Kava: an overview.J Ethnopharmacol,37(1),13-45.
  49. Singh, YN,Singh, NN(2002).Therapeutic potential of kava in the treatment of anxiety disorders.CNS Drugs,16,731-743.
  50. Soto-Otero, R,Méndez-Álvarez, E,Hermida-Ameijeiras, Á,Sánchez-Sellero, I,Cruz-Landeira, A,Lamas, MLR(2001).Inhibition of brain monoamine oxidase activity by the generation of hydroxyl radicals potential implications in relation to oxidative stress.Life Sci.,69(8),879-889.
  51. Teschke, R,Qiu, SX,Lebot, V(2011).Herbal hepatotoxicity by kava: Update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits.Dig Liver Dis,43(9),676-681.
  52. Tripathi, RKP,Ayyannan, SR(2019).Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update.Med Res Rev.,39(5),1603-1706.
  53. Uebelhack, R,Franke, L,Schewe, HJ(1998).Inhibition of platelet MAO-B by kava pyrone-enriched extract from piper methysticum forster (kava-kava).Pharmacopsychiatry,31(5),187-192.
  54. Villarinho, JG,Fachinetto, R,Pinheiro, F, de, V(2012).Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice.Prog Neuro-Psychopharmacol Biol Psychiatry,39(1),31-39.
  55. Vindis, C,Séguélas, MH,Lanier, S,Parini, A,Cambon, C(2001).Dopamine induces ERK activation in renal epithelial cells through H2O2 produced by monoamine oxidase.Kidney Int,59(1),76-86.
  56. Volgin, A,Yang, LE,Amstislavskaya, T(2020).DARK Classics in Chemical Neuroscience: Kava.ACS Chem Neurosci,11(23),3893-3904.
  57. Wang, D,Yang, LE,Wang, J(2020).Behavioral and physiological effects of acute and chronic kava exposure in adult zebrafish.Neurotoxicol Teratol,79,106881.
  58. Wang, L,Esteban, G,Ojima, M(2014).Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.Eur J Med Chem,80,543-561.
  59. Youdim, MBH,Bakhle, YS(2006).Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.Br J Pharmacol,147(Suppl 1),S287-S296.
  60. Youdim, MBH,Edmondson, D,Tipton, KF(2006).The therapeutic potential of mono-amine oxidase inhibitors.Nat Rev Neurosci,7(4),295-309.
  61. Youdim, MBH,Fridkin, M,Zheng, H(2004).Novel bifunctional drugs targeting mono-amine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.J Neural Transm,111(10-11),1455-1471.
print cancel